Psoriasis – Access & Reimbursement – Detailed, Expanded Analysis (US)
Janssen’s interleukin (IL)-12/23 inhibitor Stelara, AbbVie’s tumor necrosis factor-alpha (TNF-α) inhibitor Humira, and Novartis’s IL-17A inhibitor Cosentyx lead the U.S. psoriasis biologics market, but the approval of novel, more-effective therapies has started changing the landscape as newer biologics gain greater acceptance from treating physicians. Eli Lilly’s IL-17 inhibitor Taltz and Amgen’s oral PDE-4 inhibitor Otezla have successfully carved out space in the treatment algorithm. More-effective biologics—AbbVie’s Skyrizi and Janssen’s Tremfya—and emerging therapies in the late-phase pipeline are threatening the dominance of earlier-to-market biologics. Given the recent entry of infliximab biosimilars, along with the development of another IL-17 A/F dual inhibitor, an oral TYK2 inhibitor, and two novel topical therapies, marketers of psoriasis therapies must learn how to navigate this increasingly competitive market.
QUESTIONS ANSWERED
- Among commercially insured psoriasis patients, what percentage receive newer biological agents, and which biologics / Otezla do physicians perceive to perform the best on specific clinical and market access factors?
- How do payers cover biosimilar versions of infliximab (Pfizer’s Inflectra, Merck’s Renflexis, and Amgen’s Avsola), and how do physicians expect to prescribe these biosimilars?
- What are physician perceptions of emerging therapies such as bimekizumab, Remsima (SC), deucravacitinib, and emerging nonsteroidal topical agents with novel mechanisms of action? How do payers anticipate covering these agents?
- For psoriasis drugs with similar efficacy and safety, what economic factors most influence favorable coverage in MCOs’ largest fully insured plans?
PRODUCT DESCRIPTION
U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.
Key drugs: Humira, Enbrel, Remicade, Inflectra, Renflexis, Avsola, Cimzia, Stelara, Otezla, Cosentyx, Taltz, Siliq, Tremfya, Ilumya, Skyrizi, Remsima (SC), bimekizumab, deucravacitinib, roflumilast (topical), tapinarof
Key companies: AbbVie, Amgen, Arcutis, Bristol-Myers Squibb, Dermavant, Eli Lilly, Janssen, Merck, Pfizer, Novartis, UCB.
Table of contents
- Psoriasis - Access & Reimbursement - Detailed, Expanded Analysis (US)
- Access & Reimbursement Psoriasis US July 2022
Mohit Nasa, M.B.A., is a principal analyst on the Immune and Inflammatory Disorders team at Clarivate. He has authored content on such indications as systemic lupus erythropoiesis, psoriasis, asthma, and rheumatoid arthritis. Previously, he worked as a senior business analyst at Novartis, where he was responsible for end-to-end market assessment and related projects for Novartis’s asthma brand Xolair. Mr. Nasa holds a bachelor’s degree in pharmacy and an M.B.A. in marketing and CRM from Amity Business School in India.